Sorin: Solid Q2, plenty of opportunities despite challenging markets

BUY, Fair Value EUR2.4 (+15%)

News published on July Wednesday 31, 2013
Share on

Sorin released a solid set of results in Q2 with sales at EUR187.7m, growing 2.7% CER, at the high end of guidance (1-3% CER). This was once again driven by opposite trends in Cardiac Surgery (64% of sales, 9.4% CER) with the former cardiopulmonary division (Heart Lung Machines, Oxygenators, Autotransfusion) growing double-digits and mechanical valves being under pressure. The Cardiac Rhythm Management division (36% of sales, -7.3%) declined sharply in line with the market but we expect some recovery in H2. Regarding profitability, EBITDA margin rose to 16.6% (up 90bps) and net adjusted income was EUR14.2m. No change to the full-year guidance. We continue to believe that Sorin has some attractive opportunities in emerging markets (13% of sales, up 30%) as well as new products approvals and margins expansion.

Full report available to subscribers
Please contact  

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities